Funding for this research was provided by:
National Institutes of Health (CA009666)
National Cancer Institute (P30 CA016672)
Received: 10 August 2018
Accepted: 6 December 2018
First Online: 19 December 2018
: Not applicable
: The study protocol and all amendments were approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center (protocol #2010–0113). The study was conducted in accordance with the protocol and its amendments, Good Clinical Practice Guidelines, and the Declaration of Helsinki. All patients provided written informed consent.
: W.-J. Hwu reports funding to the institution for clinical research from Bristol-Myers Squibb, MedImmune, and Merck & Co., Inc. and serving on an advisory board for Merck & Co., Inc.Jade Homsi reports speaking and consulting with Merck & Co., Inc.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.